Condition: Hypertriglyceridemia · Sponsor: Ribotek Biopharmaceuticals (Shandong) Co., Ltd
The goal of this clinical trial is to learn if drug RBD5044 works to treat hypertriglyceridemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are: Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat hypertriglyceridemia. Participants will: Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84).
This description comes directly from the study's public registry record.
Fei Xu · +86 10 62975531 · xuf@ribolia.com
Always discuss trial participation with your own doctor first.
| Daqing People's Hospital | Daqing, Heilongjiang, China | Recruiting |
| The Fourth Hospital of Harbin Medical University | Harbin, Heilongjiang, China | Recruiting |
| The First Affiliated Hospital of Henan University of Science and Technology | Luoyang, Henan, China | Recruiting |
| Jingzhou Central Hospital | Jingzhou, Hubei, China | Recruiting |
| The First Affiliated Hospital of Nanyang Medical College | Nanyang, Nanyang, China | Recruiting |
| Yuncheng Central Hospital | Yuncheng, Shanxi, China | Recruiting |
| Lishui Central Hospital | Lishui, Zhejiang, China | Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07587788